<DOC>
	<DOCNO>NCT01338818</DOCNO>
	<brief_summary>This study evaluate long-term safety methylphenidate hydrochloride extend release adult attention deficit/hyperactivity disorder</brief_summary>
	<brief_title>Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release Adults With Attention Deficit/Hyperactivity Disorder</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Completion 40week core study CRIT124D2302 Week 40 ( End Study ) assessments Patients meet predefined criterion treatment failure , withdrawn core study , complete corestudy week 40 assessment ( Premature Discontinuation Visit ) 1 . Patients , core study , develop psychiatric condition require treatment medication may interfere study participation /or study assessment . 2 . Patients core study develop cardiovascular disorder . 3 . Pregnant woman . 4 . Patients develop seizure core study . 5 . Diagnosis glaucoma , hyperthyroidism , pheochromocytoma . 6 . Diagnosis family history Tourette 's syndrome . 7 . Patients core study develop cerebrovascular disorder cerebral aneurysm , vascular abnormality include vasculitis stroke Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Attention Deficit /Hyperactivity Disorder ,</keyword>
	<keyword>hyperactivity</keyword>
</DOC>